Trial Profile
Phase 2 Study of Erlotinib Versus Gefitinib in Advanced Non Small Cell Lung Cancer With exon21 Mutation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 May 2019 Results published in conjunction with the 55th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer